Organon & Co. (NYSE:OGN) Downgraded by Zacks Research to Strong Sell

Organon & Co. (NYSE:OGN) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Thursday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. Piper Sandler lowered Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price objective for the company. in a research report on Monday, October 27th. Morgan Stanley dropped their target price on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 11th. JPMorgan Chase & Co. reduced their price target on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a report on Tuesday, November 11th. Finally, Barclays assumed coverage on shares of Organon & Co. in a research note on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $8.38.

Organon & Co. Trading Down 1.0%

OGN opened at $8.51 on Thursday. The stock has a market cap of $2.21 billion, a PE ratio of 4.43, a PEG ratio of 1.84 and a beta of 0.58. The business has a 50 day moving average of $7.80 and a 200-day moving average of $8.73. Organon & Co. has a 52 week low of $6.18 and a 52 week high of $17.23. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Monday, November 10th. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.93 by $0.08. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.The business had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter last year, the firm posted $1.38 earnings per share. Equities research analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Organon & Co.

Institutional investors and hedge funds have recently modified their holdings of the company. Hantz Financial Services Inc. increased its position in shares of Organon & Co. by 293.8% during the 2nd quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock valued at $26,000 after purchasing an additional 1,995 shares during the last quarter. Foster Dykema Cabot & Partners LLC purchased a new position in shares of Organon & Co. during the 3rd quarter worth $29,000. Farther Finance Advisors LLC increased its stake in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after purchasing an additional 2,033 shares in the last quarter. SouthState Corp grew its holdings in Organon & Co. by 1,857.0% during the second quarter. SouthState Corp now owns 3,914 shares of the company’s stock valued at $38,000 after purchasing an additional 3,714 shares during the period. Finally, Rothschild Investment LLC raised its stake in shares of Organon & Co. by 73.1% in the third quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after buying an additional 1,646 shares during the period. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.